0000899243-23-010009.txt : 20230330
0000899243-23-010009.hdr.sgml : 20230330
20230330090007
ACCESSION NUMBER: 0000899243-23-010009
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230329
FILED AS OF DATE: 20230330
DATE AS OF CHANGE: 20230330
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MICHEL GERARD J
CENTRAL INDEX KEY: 0001235644
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16133
FILM NUMBER: 23777367
MAIL ADDRESS:
STREET 1: 420 CHIPETA WAY
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: DELCATH SYSTEMS, INC.
CENTRAL INDEX KEY: 0000872912
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 061245881
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1633 BROADWAY
STREET 2: SUITE 22C
CITY: NEW YORK
STATE: NY
ZIP: 10019
BUSINESS PHONE: (212) 489-2100
MAIL ADDRESS:
STREET 1: 1633 BROADWAY
STREET 2: SUITE 22C
CITY: NEW YORK
STATE: NY
ZIP: 10019
FORMER COMPANY:
FORMER CONFORMED NAME: DELCATH SYSTEMS INC
DATE OF NAME CHANGE: 19990607
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-03-29
0
0000872912
DELCATH SYSTEMS, INC.
DCTH
0001235644
MICHEL GERARD J
C/O DELCATH SYSTEMS, INC.,
1633 BROADWAY, SUITE 22C
NEW YORK
NY
10019
1
1
0
0
Chief Executive Officer
0
Common Stock
2023-03-29
4
P
0
19646
4.84
A
197235
D
Tranche A Warrants to Purchase Common Stock
4.50
2023-03-29
4
P
0
31110
0.125
A
2023-03-29
Common Stock
31110
31110
D
Tranche B Warrants to Purchase Common Stock
6.00
2023-03-29
4
P
0
16666
0.125
A
2023-03-29
Common Stock
16666
16666
D
The common stock and Tranche A and Tranche B Warrants were acquired in the issuer's private placement of common stock and warrants, issued as part of a unit. The per unit purchase price was $5.09, including a purchase price of $4.84 per share of common stock and $0.125 for each of the Tranche A and Tranche B Warrants. Each unit consisted of one share of common stock and an accompanying common stock warrant valued at 140% of the aggregate purchase price (the Tranche A Warrant) and an accompanying common stock warrant valued at 100% of the aggregate purchase price (the Tranche B Warrant).
The Tranche A Warrants and Tranche B Warrants are immediately exercisable.
The Tranche A Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of its receipt of written approval from the U.S. Food and Drug Administration of its New Drug Application for HEPZATO (the "FDA Approval") and (ii) March 31, 2026.
The Tranche B Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of record at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026, provided, however, if the FDA Approval occurs on or before February 15, 2024 and the Tranche A Warrants have not been exercised in full on or before March 7, 2024, then the Tranche B Warrants shall automatically expire on March 8, 2024.
/s/ Gerard Michel
2023-03-30